Policosanol in treating chronic pancreatitis on the background of pancreatic steatosis

Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S106
Author(s):  
Nadiya Byelyayeva ◽  
Natalya Gubergrits ◽  
Galina Lukashevich
2018 ◽  
Vol 12 (2) ◽  
pp. 331-336 ◽  
Author(s):  
Constantine Melitas ◽  
Mick Meiselman

Obesity, insulin resistance, and metabolic syndrome continue to increase in prevalence. Hypertriglyceridemia is commonly associated and represents a valuable marker of metabolic syndrome. An increase in subcutaneous fat deposition places patients at risk for visceral adipose deposition in sites such as the liver, heart, and pancreas. Pancreatic steatosis in the setting of metabolic syndrome is a rapidly emerging entity whose clinical spectrum remains to be defined. Hypertriglyceridemia is an accepted cause of acute pancreatitis but its role in chronic pancreatic injury remains to be explored. We present 3 patients with chronic abdominal pain and pancreatic steatosis in the setting of underlying metabolic syndrome with hypertriglyceridemia. These cases were identified in one endoscopic ultrasonographer’s practice over a 12-month period. Each patient had documented hypertriglyceridemia but no history of acute hypertriglyceride-induced pancreatitis. A history of significant alcohol exposure was carefully excluded. Each patient underwent endoscopic ultrasonography (EUS) which proved critical in delineating the spectrum of chronic pancreatic injury. Each of our patients had EUS documentation of pancreatic steatosis and sufficient criteria to establish a diagnosis of chronic pancreatitis. Intraductal pancreatic calculi were identified in all 3 patients. Our series suggests that in the setting of metabolic syndrome, chronic hypertriglyceridemia and pancreatic steatosis may be associated with chronic pancreatitis. We hypothesize that hypertriglyceridemia may provide a pathogenic role in the development of chronic pancreatic microinjury. In addition, each of our patients had EUS-documented pancreatic ductal lithiasis. To our review, these are novel findings which have yet to be reported. We believe that with an enhanced awareness, it is likely that the entity of metabolic syndrome with features of pancreatic steatosis and hypertriglyceridemia with their associated manifestations of chronic pancreatitis, including ductal lithiasis, will be widely appreciated.


Pancreas ◽  
2019 ◽  
Vol 48 (3) ◽  
pp. 420-426 ◽  
Author(s):  
Temel Tirkes ◽  
Christie Y. Jeon ◽  
Liang Li ◽  
Aron Y. Joon ◽  
Ted A. Seltman ◽  
...  

2020 ◽  
Vol 47 (2) ◽  
pp. 19-31
Author(s):  
N. B. Gubergrits ◽  
N. V. Byelyayeva ◽  
G. M. Lukashevich ◽  
P. G. Fomenko ◽  
E. V. Berezhnaya ◽  
...  

The article reveals the achievements of modern pancreatology in the field of pathogenesis, dynamics of development and treatment of chronic pancreatitis (CP). Data of genetic studies describing the most diverse genetic mutations predisposing to the appearance of CP are considered. Genetic mutations causing not only СP, but also pancreatic cancer are analyzed. Risk factors of autoimmune pancreatitis development are mentioned; features of accompanying kidney affection are described. СP conceptual model including the phase of early СP is presented. The provisions of the International Consensus on Early CP are given, the criteria for diagnosing this stage of СP using both clinical/functional criteria and visualizing research methods are listed. Pathophysiological features of pancreatic fibrogenesis are considered. The results of studies describing the peculiarities of the appearance of exocrine pancreatic insufficiency (EPI), the feasibility of determining fecal elastase-1 as a screening of EPI are analyzed. Peculiarities of EPI occurrence in osteopenia, cardiovascular disease are considered. The nuances of pancreatic enzyme replacement therapy (PERT) in the pancreatic steatosis, obesity are described, as well as its impact on the quality of life of patients with CP and EPI. Advantages of using the enteric-coated minimicrospheres and possibility of controlling the clinical manifestations of EPI, increasing body weight, improving quality of life and its duration of PERT are listed. Optimal doses of enzyme preparations during PERT are considered, results of randomized studies proving the efficacy of minimicrospherical preparations are given.


2001 ◽  
Vol 120 (5) ◽  
pp. A647-A647
Author(s):  
M WEHLER ◽  
R NICHTERLEIN ◽  
B FISCHER ◽  
M FARNBACHER ◽  
U REULBACH ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A646-A646
Author(s):  
F MAIRE ◽  
T BIENVENU ◽  
C AQUAVIVA ◽  
F TRIVIN ◽  
P LEVY

2001 ◽  
Vol 120 (5) ◽  
pp. A720-A720
Author(s):  
K RIACKEHEER ◽  
G SPARMANN ◽  
H KLEINE ◽  
H WEBER ◽  
S LIEBE ◽  
...  

1956 ◽  
Vol 31 (6) ◽  
pp. 727-745 ◽  
Author(s):  
Lloyd G. Bartholomew ◽  
Mandred W. Comfort
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document